
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
Dr. Jonathan Spergel and Prof. Arjan Bredenoord highlight the importance of different immune cells in type 2 inflammation in EoE.
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).